The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06332092
Recruitment Status : Recruiting
First Posted : March 27, 2024
Last Update Posted : April 17, 2024
Sponsor:
Information provided by (Responsible Party):
Fulgent Pharma LLC.

Tracking Information
First Submitted Date  ICMJE March 12, 2024
First Posted Date  ICMJE March 27, 2024
Last Update Posted Date April 17, 2024
Actual Study Start Date  ICMJE April 10, 2024
Estimated Primary Completion Date March 31, 2025   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 19, 2024)		 ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: Through study completion, an average of 1 year ]
To evaluate the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic HNSCC based on Objective Response Rate (ORR).
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 19, 2024)
  • BOR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: Through study completion, an average of 1 year ]
    Best Overall Response (BOR) measures the changes in tumor mass, growth (progression) or shrinkage (response) using the RECIST criteria.
  • Duration of Response (DoR) measurement [ Time Frame: Through study completion, an average of 1 year ]
    The length of time that a tumor continues to respond to treatment without the cancer growing or spreading will be recorded.
  • Progression-free Survival (PFS) measurement [ Time Frame: Through study completion, an average of 1 year ]
    The length of time to either radiological confirmed progression or death from any cause will be recorded.
  • Overall Survival (OS) measurement [ Time Frame: Through study completion, an average of 1 year ]
    The length of time to death from any cause will be recorded.
  • Disease Control Rate (DCR) analysis [ Time Frame: Through study completion, an average of 1 year ]
    The percentage of patients with advanced HNSCC who have achieved complete response, partial response and stable disease to different treatment regimens will be calculated.
  • Adverse Events (AEs) graded according to the CTCAE version 5.0 [ Time Frame: Through study completion, an average of 1 year ]
    Safety and tolerability of different dosing regiments will be assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
  • Vital Signs safety assessments [ Time Frame: Through study completion, an average of 1 year ]
    Vital signs measurements include body temperature in Fahrenheit, respiratory rate, heart rate, and systolic and diastolic blood pressure measurements. Any confirmed, clinically significant abnormal vital sign measurements must be recorded as AEs.
  • Clinical Laboratory safety assessments [ Time Frame: Through study completion, an average of 1 year ]
    Routine hematology, chemistry, and urinalysis to be performed at visits. Any confirmed, clinically significant abnormal laboratory results must be recorded as AEs.
  • ECGs safety assessment [ Time Frame: Through study completion, an average of 1 year ]
    12-lead Electrocardiograms (ECGs) should be performed before the start and after the end of FID-007 infusion. An assessment of normal, clinically significant or abnormal, not clinically significant will be recorded.
  • Area Under the Plasma Concentration Versus Time Curve (AUC) of FID-007 [ Time Frame: Cycle 2 (each cycle is 28 days) ]
    Application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient.
  • Peak Plasma Concentration (Cmax) [ Time Frame: Cycle 2 (each cycle is 28 days) ]
    Application of pharmacokinetic parameters to the safe and effective therapeutic management of drugs in an individual patient.
  • Terminal/elimination half-life (t1/2) [ Time Frame: Cycle 2 (each cycle is 28 days) ]
    Application of pharmacokinetic parameters to the safe and effective therapeutic management of drugs in an individual patient.
  • Clearance (CL) [ Time Frame: Cycle 2 (each cycle is 28 days) ]
    Application of pharmacokinetic parameters to the safe and effective therapeutic management of drugs in an individual patient.
  • Volume of Distribution (Vd) [ Time Frame: Cycle 2 (each cycle is 28 days) ]
    Application of pharmacokinetic parameters to the safe and effective therapeutic management of drugs in an individual patient.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
Official Title  ICMJE A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Brief Summary The goal of this FID-007 Clinical Trial is to compare the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). The main questions it aims to answer are: to evaluate the efficacy, and to characterize the safety and tolerability. Eligible participants will be enrolled and randomized to 1 of 2 arms of FID-007 with fixed-dose Cetuximab in each 28-day cycle.
Detailed Description

The goal of this FID-007 Randomized, Multicenter, Open-label clinical trial is to compare the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) based on objective response rate. The main questions it aims to answer are:

  • To evaluate the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients based on Best Overall Response (BOR), Duration of Response (DoR), Disease Control Rate (DCR), Progression-Free Survival (PFS), and Overall Survival (OS).
  • To characterize the pharmacokinetics (PK) of FID-007 and its metabolites (6-α-hydroxypaclitaxel and 3'-p-hydroxypaclitaxel) following administration of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic HNSCC.
  • To characterize the safety and tolerability of different dosing regimens of FID-007 in combination with Cetuximab in patients.

Eligible participants will be enrolled and randomized to 1 of 2 arms of FID-007 with fixed-dose Cetuximab (starting from Cycle 2, 500 mg/m2 intravenous [IV] infusion every 2 weeks on Days 1 and 15 of each 28-day cycle). Patients will receive FID-007 via IV infusion over 30 minutes at their assigned dose on Days 1, 8, and 15 of each 28-day cycle.

Patients will continue to receive Cetuximab and FID-007 until they meet the study drug discontinuation criteria.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Single Group Assignment
Intervention Model Description:
Two different dosing regimens of FID-007 in combination with fixed-dose Cetuximab
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Head and Neck Squamous Cell Carcinoma
Intervention  ICMJE Drug: FID007
Patients will receive FID007 via IV infusion at their assigned dose on Days 1, 8, and 15 of each 28-day cycle. Starting from Cycle 2, Cetuximab will be administered every 2 weeks on Days 1 and 15 of each 28-day cycle.
Other Name: Paclitaxel in Polyethyloxazoline Polymer; FID-007; FID007 (CN); FID 007; Nanoencapsulated Paclitaxel FID-007
Study Arms  ICMJE
  • Active Comparator: Arm A
    FID-007 (75 mg/m2) plus Cetuximab (500 mg/m2)
    Intervention: Drug: FID007
  • Active Comparator: Arm B
    FID-007 (125 mg/m2) plus Cetuximab (500 mg/m2)
    Intervention: Drug: FID007
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 19, 2024)		 46
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 31, 2025
Estimated Primary Completion Date March 31, 2025   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Ability to understand and willingness to provide informed consent before the start of any study-specific procedures.
  2. Age ≥18 years old.

  3. A diagnosis of recurrent or metastatic HNSCC at 1 of the following sites:

    1. Nasal/paranasal sinuses
    2. Nasopharynx (Epstein-Barr virus [EBV] negative only)
    3. Oral cavity
    4. Oropharynx
    5. Hypopharynx
    6. Larynx
  4. Disease progression after treatment with PD-L1-based immune checkpoint inhibitor at any time. This can be as monotherapy or in combination with chemotherapy.
  5. Measurable disease according to RECIST version 1.1.
  6. Adequate treatment washout period of ≥21 days or 5 half-lives, whichever is shorter, for prior chemotherapy, radiotherapy, hormonal therapy, biological therapy, or immunotherapy before the first dose of study drug administration. Note: Palliative radiation is permitted but not ≤7 days before the first dose of study drug.
  7. ECOG PS of 0 or 1.
  8. Recovery from any toxic effects of previous chemotherapy, targeted therapy, or radiotherapy as judged by the investigator to Grade ≤1 (except for alopecia) according to NCI CTCAE version 5.0.

  9. Adequate bone marrow and organ function defined as the following:

    Bone marrow function

    • Absolute neutrophil count ≥1500/mm3 (growth factor administration is not permitted ≤1 week before the screening assessment)
    • Platelet count ≥100,000/mm3 (platelet transfusion is not permitted ≤1 week before the screening assessment)
    • Hemoglobin ≥8 g/dL (criteria must be met without packed red blood cell transfusion ≤1 week before the screening assessment; chronic treatment with erythropoietin is permitted if the patient is on erythropoietin for ≥8 weeks)

    Blood clotting function

    • International normalized ratio (INR) ≤1.5 × upper limit of normal (ULN) and activated partial thromboplastin time ≤1.5 × ULN (except patients who are receiving therapeutic anticoagulation and whose INR should be within the therapeutic range)

    Renal function

    •Calculated clearance (using the Cockroft-Gault formula) ≥40 mL/min/1.73 m2. Actual body weight should be used for calculating creatinine clearance. For patients with a body mass index >30 kg/m2, lean body weight should be used instead

    Hepatic function

    • Total bilirubin ≤1.5 × ULN (patients with Gilbert's disease can have bilirubin >1.5 × ULN to <3 × ULN)
    • Aspartate aminotransferase/alanine aminotransferase ≤3 × ULN
  10. An estimated life expectancy of at least 3 months based on investigator judgment.
  11. Negative serum pregnancy test result at screening for female patients of childbearing potential.
  12. Willingness to abide by the contraceptive requirements in Appendix 1 of the protocol.

Exclusion Criteria:

  1. Known hypersensitivity to paclitaxel.
  2. EBV-positive nasopharyngeal cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, or squamous cell carcinoma of the salivary gland or skin, based on the patient's medical history.
  3. Received >1 prior line of anticancer therapy for recurrent or metastatic HNSCC. All patients must be previously treated with an immune checkpoint inhibitor either as monotherapy or in combination with chemotherapy. Patients treated with upfront combination chemo-immunotherapy followed by immunotherapy maintenance are considered to have received only 1 prior line of therapy. Chemotherapy given as part of treatment for locally advanced disease in the adjuvant or neoadjuvant setting is not considered a line of prior therapy for recurrent/metastatic disease. If the patient received prior treatment with Cetuximab, paclitaxel, or nab-paclitaxel in combination with radiation in the locally advanced setting and no relapse within 6 months of treatment discontinuation, enrollment is permitted if the treating physician believes that retreatment with Cetuximab or a taxane is a clinically reasonable option. However, patients who received these agents for recurrent or metastatic disease will be excluded.
  4. Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, that in the judgment of the investigator could compromise the patient's safety or the study data integrity.
  5. Preexisting sensory neuropathy of Grade >1 severity by NCI CTCAE version 5.0 criteria.
  6. Known history of uncontrolled HIV infection defined as CD4+ cells <350/mm3.
  7. Requirement of systemic steroids at daily doses >10 mg prednisone equivalent systemic exposure daily, including for control of symptoms.
  8. Use of any CYP2C8 and CYP3A4 inhibitor (eg, ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, cimetidine, ritonavir, saquinavir, indinavir, and nelfinavir) or inducer (eg, rifampicin, carbamazepine, phenytoin, efavirenz, and nevirapine) in the previous 14 days before the first dose of study drug until the last PK sample is obtained in the study.
  9. Known brain metastasis. Note: Patients whose central nervous system metastases have been treated by surgery or radiotherapy, who are no longer on corticosteroids, and who are neurologically stable are eligible.
  10. Current or recent participation in a study of an investigational product in the prior 4 weeks. Note: Patients who have completed the treatment phase of an investigational study and have entered the follow-up phase of the investigational study may participate in FID-007-003 as long as it has been ≥4 weeks before the first dose of study drug.
  11. Pregnancy, breastfeeding, or plans to become pregnant during the study or within 24 weeks after the last dose of study drug (Appendix 1 of the protocol).
  12. Plans to donate/bank or retrieve eggs (ova, oocytes) during the study or within 24 weeks after the last dose of study drug (Appendix 1 of the protocol).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Chief Scientific Officer (302) 283-1730 ryin@fulgentgenetics.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT06332092
Other Study ID Numbers  ICMJE FID-007-003
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Fulgent Pharma LLC.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Fulgent Pharma LLC.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Fulgent Clinical Sites Fulgent Pharma LLC.
PRS Account Fulgent Pharma LLC.
Verification Date April 2024

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP